Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in NYC, and a pharmacist at New York Presbyterian—Lower Manhattan Hospital.
References
- Dekavil (F8-IL10). Philogen. http://www.philogen.com/DEKAVIL.html.
- Galeazzi M, Bazzichi G, Sebastian G, et al. A phase Ib clinical trial in rheumatoid arthritis of Dekavil (F8-IL10), a novel anti-inflammatory immunocytokine. EULAR 2014. Abstract SAT0232.
- Combination Therapy of F8IL10 and Methotrexate in Rheumatoid Arthritis Patients. Clinical Trials. June 18, 2014. http://clinicaltrials.gov/ct2/show/NCT02076659.
- Barber J. FDA delays decision for Orexigen’s experimental obesity drug, shares fall. First Word Pharma. June 11, 2014. http://www.firstwordpharma.com/print/1216650?tsid=17.
- Chavis R. Mylan launches generic Actonel tables. Drug Store News. June 11, 2014. http://www.drugstorenews.com/article/mylan-launches-generic-actonel-tablets.
- UCB announces data from first seven year evaluation for Cimzia® (certolizumab pegol) in moderate to severe Crohn’s disease patients. May 5, 2014. http://www.prnewswire.com/news-releases/ucb-announces-data-from-first-seven-year-evaluation-of-cimzia-certolizumab-pegol-in-moderate-to-severe-crohns-disease-patients-257934701.html.
- Walsh N. Combo therapy boosts patient outcomes in RA. June 14, 2014. http://www.medpagetoday.com/MeetingCoverage/EULAR/46316.
- Burmester G, Bianco R, Keiserman M, et al. Tocilizumab (TCZ) as combination therapy and as monotherapy versus methotrexate in MTX-naive patients with early rheumatoid arthritis: Patient-reported outcomes (PROS) from a randomized, placebo-controlled trial. EULAR 2014. Abstract SAT0226.
- Garrett N. Bisphosphonate compliance linked to increase in femoral fractures. Rheumatology Update. June 4, 2014. http://www.rheumatologyupdate.com.au/latest-news/bisphosphonate-compliance-linked-to-increase-in-fe.
